- Home
- DOUG vs EPRX Comparison
DOUG vs EPRX Comparison
Compare DOUG & EPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOUG
- EPRX
- Stock Information
- Founded
- DOUG 1911
- EPRX 2011
- Country
- DOUG United States
- EPRX Canada
- Employees
- DOUG N/A
- EPRX N/A
- Industry
- DOUG Building operators
- EPRX
- Sector
- DOUG Real Estate
- EPRX
- Exchange
- DOUG Nasdaq
- EPRX NYSE
- Market Cap
- DOUG 142.0M
- EPRX 130.0M
- IPO Year
- DOUG N/A
- EPRX N/A
- Fundamental
- Price
- DOUG $1.63
- EPRX $3.29
- Analyst Decision
- DOUG
- EPRX Strong Buy
- Analyst Count
- DOUG 0
- EPRX 1
- Target Price
- DOUG N/A
- EPRX $9.00
- AVG Volume (30 Days)
- DOUG 491.6K
- EPRX 8.3K
- Earning Date
- DOUG 05-08-2025
- EPRX 05-07-2025
- Dividend Yield
- DOUG N/A
- EPRX N/A
- EPS Growth
- DOUG N/A
- EPRX N/A
- EPS
- DOUG N/A
- EPRX N/A
- Revenue
- DOUG $995,627,000.00
- EPRX N/A
- Revenue This Year
- DOUG $17.61
- EPRX N/A
- Revenue Next Year
- DOUG N/A
- EPRX N/A
- P/E Ratio
- DOUG N/A
- EPRX N/A
- Revenue Growth
- DOUG 4.19
- EPRX N/A
- 52 Week Low
- DOUG $1.00
- EPRX $2.20
- 52 Week High
- DOUG $2.98
- EPRX $4.48
- Technical
- Relative Strength Index (RSI)
- DOUG 46.15
- EPRX N/A
- Support Level
- DOUG $1.58
- EPRX N/A
- Resistance Level
- DOUG $1.74
- EPRX N/A
- Average True Range (ATR)
- DOUG 0.12
- EPRX 0.00
- MACD
- DOUG 0.00
- EPRX 0.00
- Stochastic Oscillator
- DOUG 56.36
- EPRX 0.00
About DOUG Douglas Elliman Inc.
Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate. Business is engaged in two operating segments Real Estate Brokerage and Corporate and other. The firm generates income from Commission and other brokerage revenue from existing home sales, Commission and other brokerage income from development marketing, Property management revenue and Title fees. It derives revenue from Real Estate Brokerage segment.
About EPRX EUPRAXIA PHARMACEUTICALS INC
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with significant unmet medical needs.